Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice

Gerhard Zugmaier, Soonmyoung Paik, George Wilding, Cornelius Knabbe, Mozeena Bano, Ruth Lupu, Bernd Deschauer, Marc E Lippman, Robert B. Dickson, Marc Lippman

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

While stimulating the growth of fibroblasts. transforming growth factor β1 (TGF-β1) inhibits the growth of various normal and malignant cell lines in vitro. We studied the effects of TGF-β1 in vivo. The level of TGF-β1 in serum was maximally elevated 2 h after injecting 1 μCi of 125I-TGF-β1 into the peritoneal cavity of nude mice. Five h after the i.p. administration of 10 μg of unlabeled TGF-β1, 20 ng/ml of TGF-β-like material in serum were detected by a radioreceptor assay on A549 lung carcinoma cells. Trichloroacetic acid-precipitable 1251-TGF-β1 was taken up by liver, spleen, lungs, kidneys, and tumor tissue but not by the brain. At doses exceeding 2 μg/day, TGF-β1 induced a generalized interstitial fibrosis and a cachexia, which was not mediated by elevated serum levels of tumor necrosis factor α as determined by Western blot analysis and enzyme-linked immunosorbent assay. A total of 200,000 cells of the estrogen receptor-negative human breast cancer line MDA-MB-231, which had been shown to be maximally growth inhibited in vitro by 40 PM TGF-β1 and to have high-affinity receptors (9, 11, 12), were injected into the mammary fat pad of each nude mouse. The duration of treatment was 16 days with ten animals in the control group and five animals in the treated groups. The dose ranged from 1 to 4 μg per animal daily. The treatment was started 24 h after the injection of the tumor cells. Tumor growth was not significantly affected at either nontoxic or toxic doses of TGF-β1. Thus, we have demonstrated that TGF-β1, apart from being a local growth factor, has systemic effects, such as cachexia and multiple fibrosis. Its role as an antitumor agent may be limited.

Original languageEnglish
Pages (from-to)3590-3594
Number of pages5
JournalCancer Research
Volume51
Issue number13
StatePublished - Jul 1 1991
Externally publishedYes

Fingerprint

Cachexia
Transforming Growth Factors
Nude Mice
Fibrosis
Growth
Serum
Neoplasms
Lung
Radioligand Assay
Trichloroacetic Acid
Poisons
Peritoneal Cavity
Estrogen Receptors
Antineoplastic Agents
Adipose Tissue
Intercellular Signaling Peptides and Proteins
Breast
Spleen
Tumor Necrosis Factor-alpha
Fibroblasts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zugmaier, G., Paik, S., Wilding, G., Knabbe, C., Bano, M., Lupu, R., ... Lippman, M. (1991). Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Research, 51(13), 3590-3594.

Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. / Zugmaier, Gerhard; Paik, Soonmyoung; Wilding, George; Knabbe, Cornelius; Bano, Mozeena; Lupu, Ruth; Deschauer, Bernd; Lippman, Marc E; Dickson, Robert B.; Lippman, Marc.

In: Cancer Research, Vol. 51, No. 13, 01.07.1991, p. 3590-3594.

Research output: Contribution to journalArticle

Zugmaier, G, Paik, S, Wilding, G, Knabbe, C, Bano, M, Lupu, R, Deschauer, B, Lippman, ME, Dickson, RB & Lippman, M 1991, 'Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice', Cancer Research, vol. 51, no. 13, pp. 3590-3594.
Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R et al. Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Research. 1991 Jul 1;51(13):3590-3594.
Zugmaier, Gerhard ; Paik, Soonmyoung ; Wilding, George ; Knabbe, Cornelius ; Bano, Mozeena ; Lupu, Ruth ; Deschauer, Bernd ; Lippman, Marc E ; Dickson, Robert B. ; Lippman, Marc. / Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. In: Cancer Research. 1991 ; Vol. 51, No. 13. pp. 3590-3594.
@article{0adec088059a4a75a3cf567c78ffa5d4,
title = "Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice",
abstract = "While stimulating the growth of fibroblasts. transforming growth factor β1 (TGF-β1) inhibits the growth of various normal and malignant cell lines in vitro. We studied the effects of TGF-β1 in vivo. The level of TGF-β1 in serum was maximally elevated 2 h after injecting 1 μCi of 125I-TGF-β1 into the peritoneal cavity of nude mice. Five h after the i.p. administration of 10 μg of unlabeled TGF-β1, 20 ng/ml of TGF-β-like material in serum were detected by a radioreceptor assay on A549 lung carcinoma cells. Trichloroacetic acid-precipitable 1251-TGF-β1 was taken up by liver, spleen, lungs, kidneys, and tumor tissue but not by the brain. At doses exceeding 2 μg/day, TGF-β1 induced a generalized interstitial fibrosis and a cachexia, which was not mediated by elevated serum levels of tumor necrosis factor α as determined by Western blot analysis and enzyme-linked immunosorbent assay. A total of 200,000 cells of the estrogen receptor-negative human breast cancer line MDA-MB-231, which had been shown to be maximally growth inhibited in vitro by 40 PM TGF-β1 and to have high-affinity receptors (9, 11, 12), were injected into the mammary fat pad of each nude mouse. The duration of treatment was 16 days with ten animals in the control group and five animals in the treated groups. The dose ranged from 1 to 4 μg per animal daily. The treatment was started 24 h after the injection of the tumor cells. Tumor growth was not significantly affected at either nontoxic or toxic doses of TGF-β1. Thus, we have demonstrated that TGF-β1, apart from being a local growth factor, has systemic effects, such as cachexia and multiple fibrosis. Its role as an antitumor agent may be limited.",
author = "Gerhard Zugmaier and Soonmyoung Paik and George Wilding and Cornelius Knabbe and Mozeena Bano and Ruth Lupu and Bernd Deschauer and Lippman, {Marc E} and Dickson, {Robert B.} and Marc Lippman",
year = "1991",
month = "7",
day = "1",
language = "English",
volume = "51",
pages = "3590--3594",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice

AU - Zugmaier, Gerhard

AU - Paik, Soonmyoung

AU - Wilding, George

AU - Knabbe, Cornelius

AU - Bano, Mozeena

AU - Lupu, Ruth

AU - Deschauer, Bernd

AU - Lippman, Marc E

AU - Dickson, Robert B.

AU - Lippman, Marc

PY - 1991/7/1

Y1 - 1991/7/1

N2 - While stimulating the growth of fibroblasts. transforming growth factor β1 (TGF-β1) inhibits the growth of various normal and malignant cell lines in vitro. We studied the effects of TGF-β1 in vivo. The level of TGF-β1 in serum was maximally elevated 2 h after injecting 1 μCi of 125I-TGF-β1 into the peritoneal cavity of nude mice. Five h after the i.p. administration of 10 μg of unlabeled TGF-β1, 20 ng/ml of TGF-β-like material in serum were detected by a radioreceptor assay on A549 lung carcinoma cells. Trichloroacetic acid-precipitable 1251-TGF-β1 was taken up by liver, spleen, lungs, kidneys, and tumor tissue but not by the brain. At doses exceeding 2 μg/day, TGF-β1 induced a generalized interstitial fibrosis and a cachexia, which was not mediated by elevated serum levels of tumor necrosis factor α as determined by Western blot analysis and enzyme-linked immunosorbent assay. A total of 200,000 cells of the estrogen receptor-negative human breast cancer line MDA-MB-231, which had been shown to be maximally growth inhibited in vitro by 40 PM TGF-β1 and to have high-affinity receptors (9, 11, 12), were injected into the mammary fat pad of each nude mouse. The duration of treatment was 16 days with ten animals in the control group and five animals in the treated groups. The dose ranged from 1 to 4 μg per animal daily. The treatment was started 24 h after the injection of the tumor cells. Tumor growth was not significantly affected at either nontoxic or toxic doses of TGF-β1. Thus, we have demonstrated that TGF-β1, apart from being a local growth factor, has systemic effects, such as cachexia and multiple fibrosis. Its role as an antitumor agent may be limited.

AB - While stimulating the growth of fibroblasts. transforming growth factor β1 (TGF-β1) inhibits the growth of various normal and malignant cell lines in vitro. We studied the effects of TGF-β1 in vivo. The level of TGF-β1 in serum was maximally elevated 2 h after injecting 1 μCi of 125I-TGF-β1 into the peritoneal cavity of nude mice. Five h after the i.p. administration of 10 μg of unlabeled TGF-β1, 20 ng/ml of TGF-β-like material in serum were detected by a radioreceptor assay on A549 lung carcinoma cells. Trichloroacetic acid-precipitable 1251-TGF-β1 was taken up by liver, spleen, lungs, kidneys, and tumor tissue but not by the brain. At doses exceeding 2 μg/day, TGF-β1 induced a generalized interstitial fibrosis and a cachexia, which was not mediated by elevated serum levels of tumor necrosis factor α as determined by Western blot analysis and enzyme-linked immunosorbent assay. A total of 200,000 cells of the estrogen receptor-negative human breast cancer line MDA-MB-231, which had been shown to be maximally growth inhibited in vitro by 40 PM TGF-β1 and to have high-affinity receptors (9, 11, 12), were injected into the mammary fat pad of each nude mouse. The duration of treatment was 16 days with ten animals in the control group and five animals in the treated groups. The dose ranged from 1 to 4 μg per animal daily. The treatment was started 24 h after the injection of the tumor cells. Tumor growth was not significantly affected at either nontoxic or toxic doses of TGF-β1. Thus, we have demonstrated that TGF-β1, apart from being a local growth factor, has systemic effects, such as cachexia and multiple fibrosis. Its role as an antitumor agent may be limited.

UR - http://www.scopus.com/inward/record.url?scp=0026002646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026002646&partnerID=8YFLogxK

M3 - Article

C2 - 2054795

AN - SCOPUS:0026002646

VL - 51

SP - 3590

EP - 3594

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -